N-terminal pro-brain natriuretic peptide is associated with a future diagnosis of cancer in patients with coronary artery disease

Biblos-e Archivo/Manakin Repository

Show simple item record

dc.contributor.author Tuñón, José
dc.contributor.author Higueras, Javier
dc.contributor.author Tarín, Nieves
dc.contributor.author Cristóbal, Carmen
dc.contributor.author Lorenzo, Óscar
dc.contributor.author Blanco-Colio, Luis
dc.contributor.author Martín-Ventura, José Luis
dc.contributor.author Huelmos, Ana
dc.contributor.author Alonso, Joaquín
dc.contributor.author Aceña, Álvaro
dc.contributor.author Pello, Ana María
dc.contributor.author Carda, Rocío
dc.contributor.author Asensio, Dolores
dc.contributor.author Mahillo, Ignacio
dc.contributor.author López Bescós, Lorenzo
dc.contributor.author Egido, Jesús
dc.contributor.author Farré, Jerónimo
dc.contributor.other UAM. Departamento de Medicina es_ES
dc.contributor.other Instituto de Investigación Sanitaria Fundación Jiménez Díaz (ISS-FJD) es_ES
dc.date.accessioned 2016-07-26T17:18:10Z
dc.date.available 2016-07-26T17:18:10Z
dc.date.issued 2015-06-05
dc.identifier.citation PLOS ONE 10.6 (2015); e0126741 en_US
dc.identifier.issn 1932-6203 es_ES
dc.identifier.uri http://hdl.handle.net/10486/672235
dc.description.abstract Objective Several papers have reported elevated plasma levels of natriuretic peptides in patients with a previous diagnosis of cancer. We have explored whether N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma levels predict a future diagnosis of cancer in patients with coronary artery disease (CAD). Methods We studied 699 patients with CAD free of cancer. At baseline, NT-proBNP, galectin-3, monocyte chemoattractant protein-1, soluble tumor necrosis factor-like weak inducer of apoptosis, high-sensitivity C-reactive protein, and high-sensitivity cardiac troponin I plasma levels were assessed. The primary outcome was new cancer diagnosis. The secondary outcome was cancer diagnosis, heart failure requiring hospitalization, or death. Results After 2.15±0.98 years of follow-up, 24 patients developed cancer. They were older (68.5 [61.5, 75.8] vs 60.0 [52.0, 72.0] years; p=0.011), had higher NT-proBNP (302.0 [134.8, 919.8] vs 165.5 [87.4, 407.5] pg/ml; p=0.040) and high-sensitivity C-reactive protein (3.27 [1.33, 5.94] vs 1.92 [0.83, 4.00] mg/L; p=0.030), and lower triglyceride (92.5 [70.5, 132.8] vs 112.0 [82.0, 157.0] mg/dl; p=0.044) plasma levels than those without cancer. NT-proBNP (Hazard Ratio [HR]=1.030; 95% Confidence Interval [CI]=1.008-1.053; p=0.007) and triglyceride levels (HR=0.987; 95%CI=0.975-0.998; p=0.024) were independent predictors of a new cancer diagnosis (multivariate Cox regression analysis). When patients in whom the suspicion of cancer appeared in the first one-hundred days after blood extraction were excluded, NT-proBNP was the only predictor of cancer (HR=1.061; 95% CI=1.034-1.088; p<0.001). NT-proBNP was an independent predictor of cancer, heart failure, or death (HR=1.038; 95%CI=1.023-1.052; p<0.001) along with age, and use of insulin and acenocumarol. Conclusions NT-proBNP is an independent predictor of malignancies in patients with CAD. New studies in large populations are needed to confirm these findings en_US
dc.description.sponsorship This work was supported by grants from Fondo de Investigaciones Sanitarias (PI05/0451, PI05/1497,PI05/2475, PI05/1043, PS09/01405, PI10/ 00072, and PI10/0234, PI14/1567, Programa de Estabilización to LBC); Spanish Society of Cardiology and Spanish Heart Foundation; Spanish Society of Arteriosclerosis; RECAVA (RD06/0014/0035, www. recava.com); Fundación Lilly; and Instituto de Salud Carlos III FEDER (FJD biobank: RD09/0076/00101). en_US
dc.format.extent 14 pag. es_ES
dc.format.mimetype application/pdf en
dc.language.iso eng en
dc.publisher Public Library of Science es_ES
dc.relation.ispartof PLoS ONE en_US
dc.rights © 2015 Tuñón et al. es_ES
dc.subject.other Natriuretic peptides en_US
dc.subject.other Cancer en_US
dc.subject.other Coronary artery disease en_US
dc.title N-terminal pro-brain natriuretic peptide is associated with a future diagnosis of cancer in patients with coronary artery disease en_US
dc.type article en
dc.subject.eciencia Medicina es_ES
dc.relation.publisherversion http://dx.doi.org/10.1371/journal.pone.0126741 es_ES
dc.identifier.doi 10.1371/journal.pone.0126741 es_ES
dc.identifier.publicationfirstpage e0126741 es_ES
dc.identifier.publicationissue 6 es_ES
dc.identifier.publicationlastpage e0126741 es_ES
dc.identifier.publicationvolume 10 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion en
dc.rights.cc Reconocimiento es_ES
dc.rights.accessRights openAccess en
dc.authorUAM Aceña Navarro, Álvaro (279732)
dc.authorUAM Tuñón Fernández, José Luis (258858)

Files in this item


This item appears in the following Collection(s)

Show simple item record